Expression of endoglin in primary endometrial cancer

Oncology

Volumn 81, Issue 3-4, 2011, Pages 243-250

  Zakrzewski, Piotr K ^a   Cygankiewicz, Adam I ^a   Mokrosiński, Jacek ^a   Nowacka Zawisza, Maria ^a   Semczuk, Andrzej ^b   Rechberger, Tomasz ^b   Krajewska, Wanda M ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

ELISA; Endoglin CD105; Endometrial cancer; Quantitative PCR; Transforming growth factor

Indexed keywords

ENDOGLIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MYOMETRIUM; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 81555235446     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000334240     Document Type: Article

References (78)

1. Cho KR, Ellenson LH: Molecular biology; in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, ed 5. Springer, 2002, pp 1277-1300.
2. Milde-Langosch K, Riethdorf S: Role of cellcycle regulatory proteins in gynecological cancer. J Cell Physiol 2003; 196: 224-244.
3. Padua D, Massague J: Roles of TGFbeta in metastasis. Cell Res 2009; 19: 89-102.
4. Massague J: TGFbeta in cancer. Cell 2008; 134: 215-230.
5. Chin D, Boyle GM, Parsons PG, Coman WB: What is transforming growth factor-beta (TGF-beta)? Br J Plast Surg 2004; 57: 215-221.
6. Dennler S, Goumans MJ, ten Dijke P: Transforming growth factor beta signal transduction. J Leukoc Biol 2002; 71: 731-740.
7. Yue J, Mulder KM: Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 2001; 91: 1-34.
8. Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
9. Marra F, Bonewald LF, Park-Snyder S, Park IS, Woodruff KA, Abboud HE: Characterization and regulation of the latent transforming growth factor-beta complex secreted by vascular pericytes. J Cell Physiol 1996; 166: 537-546.
10. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM: Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23: 1024-1035.
11. De Caestecker M: The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004; 15: 1-11.
12. ten Dijke P, Hill CS: New insights into TGFbeta- Smad signalling. Trends Biochem Sci 2004; 29: 265-273.
13. Govinden R, Bhoola KD: Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003; 98: 257-265.
14. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
15. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K: Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002; 7: 1191-1204.
16. Bernabeu C, Lopez-Novoa JM, Quintanilla M: The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; 1792: 954-973.
17. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M: Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19.
18. Barbara NP, Wrana JL, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584-594.
19. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, Burn J, Diamond AG: Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217: 42-53.
20. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002; 277: 29197-29209.
21. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
22. Van LB, Franke D, Svergun DI, Han T, Hwang HY, Kim KK: Structural and functional characterization of soluble endoglin receptor. Biochem Biophys Res Commun 2009; 383: 386-391.
23. Fonsatti E, Del VL, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M: Endoglin: An accessory component of the TGFbeta- binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7.
24. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005; 36: 955-961.
25. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-1634.
26. St-Jacques S, Forte M, Lye SJ, Letarte M: Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 1994; 51: 405-413.
27. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51: 268-275.
28. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N: Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59: 856-861.
29. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI: Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008; 14: 3785-3791.
30. Marioni G, D'Alessandro E, Giacomelli L, Staffieri A: CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J Oral Pathol Med 2010; 39: 361-367.
31. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007; 127: 572-579.
32. Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska- Korczala K: Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol 2008; 59(suppl 4):45-51.
33. Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG, Gorter A: Expression of endoglin (CD105) in cervical cancer. Br J Cancer 2009; 100: 1617-1626.
34. Takase Y, Kai K, Masuda M, Akashi M, Tokunaga O: Endoglin (CD105) expression and angiogenesis status in small cell lung cancer. Pathol Res Pract 2010; 206: 725-730.
35. Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R: Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal 2011; 23: 683-699.
36. Goumans MJ, Liu Z, ten Dijke P: TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009; 19: 116-127.
37. Pardali K, Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775: 21-62.
38. Stover DG, Bierie B, Moses HL: A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007; 101: 851-861.
39. Bierie B, Moses HL: TGF-beta and cancer. Cytokine Growth Factor Rev 2006; 17: 29-40.
40. Elliott RL, Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
41. Akhurst RJ, Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 2001; 11:S44-S51.
42. Derynck R, Akhurst RJ, Balmain A: TGFbeta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
43. Wieser R: The transforming growth factorbeta signaling pathway in tumorigenesis. Curr Opin Oncol 2001; 13: 70-77.
44. De Caestecker M, Piek E, Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-1402.
45. Massague J, Blain SW, Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
46. Kirkbride KC, Ray BN, Blobe GC: Cell-surface co-receptors: Emerging roles in signaling and human disease. Trends Biochem Sci 2005; 30: 611-621.
47. Erdem O, Taskiran C, Onan MA, Erdem M, Guner H, Ataoglu O: CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 2006; 103: 1007-1011.
48. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska WM: TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol Oncol 2004; 95: 173-180.
49. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Jakowicki JA, Krajewska WM: Expression and intracellular localization of Smad proteins in human endometrial cancer. Oncol Rep 2003; 10: 1539-1544.
50. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Jakowicki JA, Krajewska WM: Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. Cancer Lett 2002; 186: 231-239.
51. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-104.
52. Tavassoli FA, Devilee P (eds): World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IACR Press, 2003, pp 218-226.
53. Zakrzewski PK, Morkosinski J, Cygankiewicz AI, Semczuk A, Rechberger T, Skomra D, Krajewska WM: Dysregulation of betaglycan expression in primary human endometrial carcinomas. Cancer Invest 2011; 29: 137-144.
54. Jonker L, Arthur HM: Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev 2002; 110: 193-196.
55. Perlingeiro RC: Endoglin is required for hemangioblast and early hematopoietic development. Development 2007; 134: 3041-3048.
56. Nomura-Kitabayashi A, Anderson GA, Sleep G, Mena J, Karabegovic A, Karamath S, Letarte M, Puri MC: Endoglin is dispensable for angiogenesis, but required for endocardial cushion formation in the midgestation mouse embryo. Dev Biol 2009; 335: 66-77.
57. McDonald J, Damjanovich K, Millson A, Wooderchak W, Chibuk J, Stevenson D, Gedge F, Bayrak-Toydemir P: Molecular diagnosis in hereditary hemorrhagic telangiectasia: Findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet 2011; 79: 335-344.
58. Mancini ML, Terzic A, Conley BA, Oxburgh LH, Nicola T, Vary CP: Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn 2009; 238: 2479-2493.
59. Wooderchak W, Gedge F, McDonald M, Krautscheid P, Wang X, Malkiewicz J, Bukjiok CJ, Lewis T, Bayrak-Toydemir P: Hereditary hemorrhagic telangiectasia: Two distinct ENG deletions in one family. Clin Genet 2010; 78: 484-489.
60. Shovlin CL: Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
61. Bernabeu C, Conley BA, Vary CP: Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007; 102: 1375-1388.
62. Guo B, Kumar S, Li C, Slevin M, Kumar P: CD105 (endoglin), apoptosis, and stroke. Stroke 2004; 35:e94-e95.
63. Dziewulska D, Rafalowska J: Role of endoglin and transforming growth factor-beta in progressive white matter damage after an ischemic stroke. Neuropathology 2006; 26: 298-306.
64. Hertig A, Liere P: New markers in preeclampsia. Clin Chim Acta 2010; 411: 1591-1595.
65. Gu Y, Lewis DF, Wang Y: Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-266.
66. Tian F, Zhou AX, Smits AM, Larsson E, Goumans MJ, Heldin CH, Boren J, Akyurek LM: Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun 2010; 392: 283-288.
67. Li C, Issa R, Kumar P, Hampson IN, Lopez- Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 116: 2677-2685.
68. Eccles SA, Welch DR: Metastasis: Recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757.
69. Yang L, Leung AC, Ko JM, Lo PH, Tang JC, Srivastava G, Oshimura M, Stanbridge EJ, Daigo Y, Nakamura Y, Tang CM, Lau KW, Law S, Lung ML: Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene 2005; 24: 697-705.
70. Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, Nakamura Y, Qi RZ, Miller LD, Liu ET, Wang LD, Li JL, Law S, Tsao SW, Lung ML: Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer 2008; 122: 587-594.
71. Wong VC, Chan PL, Bernabeu C, Law S, Wang LD, Li JL, Tsao SW, Srivastava G, Lung ML: Identification of an invasion and tumorsuppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer 2008; 123: 2816-2823.
72. Romero D, Terzic A, Conley BA, Craft C, Jovanovic B, Bergan R, Vary CP: Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 2010; 31: 359-66.
73. Craft CS, Romero D, Vary CP, Bergan RC: Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 2007; 26: 7240-7250.
74. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC: Overexpression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002; 21: 8272-8281.
75. ten Dijke P, Arthur HM: Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869.
76. Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F: Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 2009; 55: 594-599.
77. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 2006; 56: 717-723.
78. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM: Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.